Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAC vs RIC in AML or MDS
NCT01339910Phase 3Terminated
- Sponsor
- Medical College of Wisconsin
- Start
- Jun 2011
- Primary completion
- Jan 2017
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of fludarabine, busulfan, melphalan in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Medical College of Wisconsin. Started Jun 2011; status: terminated.
02
Drugs
fludarabinebusulfanmelphalan
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01339910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01339910.